Cottonseed oil alleviates ischemic stroke injury by inhibiting the inflammatory activation of microglia and astrocyte

doi:10.21203/rs.3.rs-21921/v1

Download PDF

Research

Cottonseed oil alleviates ischemic stroke injury by inhibiting the inflammatory activation of microglia and astrocyte

https://doi.org/10.21203/rs.3.rs-21921/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 11 Sep, 2020

Read the published version in Journal of Neuroinflammation →

You are reading this latest preprint version

Background: Ischemic stroke is the second leading cause of death globally. The narrow time window for administering effective thrombolytic therapy motivates the search for alternative prevention strategies. Microglia and astrocyte activation-mediated inflammation play a pivotal role in ischemic stroke injury. Cottonseed oil (CSO) has been shown to exert anti-inflammatory effects against peripheral tissue injury, although CSO is mostly used as a solvent for lipid-soluble drugs. However, the role of CSO in neuroprotection against stroke has not been previously reported.

Methods: We treated adult male rats with CSO (1.3 ml/kg, subcutaneous injection, once every other day for 3 weeks) and then constructed a middle cerebral artery occlusion (MCAO) model followed by 24 hours of reperfusion. Then we measured the neurological scores, infarction volume, neuronal injury and brain edema; we also measured the levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), degree of microglial and astrocytic activation, protein expression levels of Toll-like receptor 4 (TLR4), NF-κB and C3d, and the presence of A1 type astrocytes and A2 type astrocytes.

Results: We found that CSO treatment significantly improved the neurological deficit, reduced infarction volume, and alleviated neuronal injuries, blood–brain barrier (BBB) disruption and brain edema. Additionally, CSO treatment significantly reduced microglial and astrocytic activation, inhibited TLR4 and NF-κB protein expression, and reduced the release of IL-1β, IL-6, and TNF-α. Finally, CSO treatment significantly decreased the number of C3d/glial fibrillary acidic protein (GFAP)-positive cells and C3d protein expression, and increased the number of S100A10/GFAP-positive cells.

Conclusion: Our results first found that CSO treatment alleviated ischemic stroke injury by inhibiting TLR4/NF-κB pathway-mediated microglial and astrocytic activation and inflammation, and by reducing A1 phenotype neurotoxic astrocyte activation, suggesting that CSO could be a new strategy in the prevention of ischemic stroke.

Neurobiology of Disease

Cottonseed Oil (CSO)

Ischemic Stroke

Neuroinflammation

Microglia

Astrocyte

Neuroprotection

Stroke contributes an important source of global mortality and disability burden, with 10.3 million new strokes per year [1]. Currently, thrombolytic therapy is still the most effective treatment for ischemic stroke, but only a small number of patients receive effective thrombolytic therapy within its narrow therapy time window (4 to 6 hours) after stroke onset [2, 3]. Therefore, it is critical to develop effective prevention strategies.

Cottonseed oil (CSO), a valuable type of vegetable oil, is made up of linoleic acid (52–65%), oleic acid (25–36%) and palmitic acid (6–8%) [4]. In previous studies, CSO was mostly used as the solvent for lipid-soluble drugs such as estrogen and ketorolac [5, 6]. However, several studies found that CSO exerted protective effects against peripheral tissue injury such as gastrointestinal disease mainly by reducing inflammatory response [7, 8]. Additionally, while high lipid intake has been suggested as one of the main factors leading to atherosclerosis, this is not the case with diets containing CSO as a source of fat [9]. However, the specific effects and underlying mechanisms by which CSO treatment may alleviate ischemic stroke injury have rarely been studied.

A number of both of clinical trials and basic researches have shown that microglial and astrocytic activation mediate the inflammation responses which underpin ischemic stroke injury [10, 11, 12]. For example, inhibiting microglia and astrocyte activation alleviates ischemic stroke injury by reducing inflammation responses in the central nerve system (CNS) [13, 14]. Toll-like receptor 4 (TLR4) and nuclear factor kappa B (NF-κB) have been identified as the key molecules leading to microglia and astrocyte activation following ischemic stroke [15, 16]. Recent studies found that ischemic stroke induced two different polarized states of reactive astrocytes, which were termed neurotoxic A1 type and neuroprotective A2 type, respectively [17]. A1 type astrocytes, which are induced by the IL-1α, TNFα and C1q that are secreted by activated microglia, release the neurotoxic complement C3d directly, leading to neuron death. Inhibiting the activation of A1 type astrocytes exerted significant neuroprotective effects [17, 18]. These findings indicate the importance of modulating the activation of microglia and astrocytes for ischemic stroke treatment. However, the role and mechanism of CSO on microglial and astrocytic activation-mediated inflammation responses after ischemic stroke injury have not been reported.

To address these issues, we treated male rats with CSO and then performed middle cerebral artery occlusion (MCAO). We measured neurological scores, infarction volume, neuronal injury and brain edema; we also measured levels of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), degree of microglial and astrocytic activation, protein expression levels of Toll-like receptor 4 (TLR4), NF-κB and C3d, and the presence of A1 type astrocytes and A2 type astrocytes.

1. Animals

One hundred and eighty four male adult SD rats weighing 280–350 g were obtained from the Laboratory Animal Center of Chinese PLA General Hospital. These rats were randomly assigned to four groups according to whether they received CSO treatment and/or underwent middle cerebral artery occlusion (MCAO) and reperfusion injury (n=46 per group): Sham group without any treatment (Sham-Con), Sham plus CSO treatment group (Sham-CSO), MCAO-R injury group without treatment (MCAO-Con), MCAO-R injury plus CSO treatment group (MCAO-CSO). Rats were housed according to the standardized conditions. All experimental procedures strictly complied with relevant ethical regulations and were approved by the Ethics Committee for Animal Experimentation of the Chinese PLA General Hospital.

2. CSO treatment

The rats in Sham-CSO and MCAO-CSO groups received subcutaneous injection of 1.3 ml/kg cotton seed oil (CSO) (J&K, China) every other day for 3 weeks. Researchers performing animal experiments were blinded to the treatment. The concentrations selected in this study were based on the concentrations as the solvent administered in previous study [5].

3. Middle cerebral artery occlusion and reperfusion (MCAO-R)

The rats in MCAO-Con and MCAO-CSO groups received MCAO-R injury as previously described [15]. Rats were anesthetized with 10 % chloral hydrate (3ml/kg), and the body temperatures were continuously monitored and maintained at 36.5–37.5 °C with a thermostatic blanket. Following 1 h of transient occlusion, cerebral blood flow was restored by removing the suture for 24 h. Regional cerebral blood flow was monitored by laser-Doppler flowmetry (Supplementary Fig. 1). Only the rats whose mean cortical cerebral blood ﬂow decreased to 20% of the pre-ischemic value and recovered to 80% of the baseline after reperfusion were used for data analysis.

4. Bederson Test

Bederson Test was performed 24 h after reperfusion to evaluate neurobehavioral deficits as previously described (n=10) [19]. The neurological evaluation was scored using a 5-point scale: 0, no neurological deficit; 1, failure to extend left forepaw fully; 2, circling to the left; 3, inability to bear weight on the left; 4, no spontaneous walking with depressed level of consciousness.

5. Assessment of infarct volume

After neurological score, infarct volume was assessed via 2,3,5-triphenyltetrazolium chloride (TTC) staining as previously described (n=10) [20]. Then the brain slices were photographed, and infarct volume (the unstained areas) was determined using image analysis software (Adobe Photoshop CS6). Corrections were made for swelling, and relative infarct size was determined based on the following equation: relative infarct size=(contralateral area－ipsilateral non-infarct area)/contralateral area.

6. HE Staining

Hematoxylin and eosin (HE) Staining was used to detect the pathological changes in the ischemic penumbra 24h after reperfusion (n=5). Briefly, the rats were anesthetized as above, and the brains were fixed via transcardial perfusion with 0.9% cold heparinized saline and 4% paraformaldehyde, paraffin-embedded, and sectioned at a thickness of 4 μm for HE staining, Nissl staining and TUNEL staining. Then the sections were stained with HE and the number of HE-positive cells in the ischemic penumbra was counted in 5 different fields for each section in a blinded manner using a light microscope (BX51; Olympus, Tokyo, Japan).

7. Nissl Staining

Nissl staining was applied to observe neuronal morphologic changes in the ischemic penumbra 24h after reperfusion (n=5). The experimental steps were strictly performed according to the manufacturer’s manual of the Nissl staining kit (#G1430, Solarbio, China). The total number of Nissl-positive neurons in the penumbra were counted in 5 different fields of view for each section by an observer blinded to the treatment group manner via a light microscopy (BX51; Olympus, Tokyo, Japan).

8. TUNEL Staining

TUNEL Staining was performed to observe cell apoptosis in the ischemic penumbra 24h after reperfusion (n=5). TUNEL staining was administered according to the manufacturer’s instructions of In Situ Cell Death Detection kit (Roche Diagnostics, Germany). TUNEL-positive neurons/DAPI were regarded as an apoptosis index. The number of TUNEL-positive cells in the ischemic penumbra were counted in 5 different fields of view for each section in a blind manner via a light microscopy (BX51; Olympus, Tokyo, Japan).

9. Immunofluorescence Staining

Immunofluorescence staining was performed on frozen coronal sections of rat brains to quantify cells in the ischemia penumbra 24h after reperfusion (n=5). After post-fixation and concentration gradient dehydration, the brains were cut into 10-μm-thick sections using a Leica CM1900 frozen slicer. The brain sections were washed three times with PBS and then incubated overnight at 4 °C in a humidified atmosphere with primary antibodies. The following primary antibodies were used: mouse anti-NeuN (1:200; Millipore, USA), mouse anti-GFAP (1:200; Cell Signaling Technology, USA), rabbit anti-Iba1 (1:500; Wako, Japan), rabbit anti-TNF-α (1:100; Cell Signaling Technology ), goat anti-C3d (1:50; RD Systems, USA), rabbit anti-S100A10 (1:50; Invitrogen, USA). Then, the samples were incubated with mixtures of Alexa-488 (red, Invitrogen) or Alexa-594 (red, Invitrogen) and Alexa-647 (green, Invitrogen)-conjugated donkey anti-goat or anti-rabbit and donkey anti-mouse secondary antibodies for 2 h in the dark at room temperature. The sections were mounted with 50% glycerol and examined under a fluorescence microscope. The total number of Neun-positive neurons, GFAP-positive astrocytes, IBA1-positive microglia, C3d/GFAP-positive cells and S100A10/GFAP-positive cells respectively in the ischemic penumbra were counted in 5 different fields of view for each section by an observer blinded to the treatment group manner via light microscopy (BX51; Olympus, Tokyo, Japan).

10. Brain Water Content

Brain water content was measured by the wet/dry weight method [21]. Rats (n=6) were anesthetized and the brains were removed quickly at 24 h after reperfusion. A coronal brain slice (about 5 mm thick) 3 mm from the frontal pole was cut and divided into the ischemic and non-ischemic hemispheres. Ischemic hemisphere samples were weighed wet and then dried at 100℃ in a vacuum oven for 48 h and reweighed. Brain water content (%) was calculated as ((wet weight-dry weight)/wet weight) ×100%.

11. Determination of the blood–brain barrier (BBB) Permeability

Immediately after reperfusion, 4 ml/kg of 2% Evans blue (Sigma Aldrich) was injected into the right jugular vein (n=6). The animals were euthanatized 24h after reperfusion. For Evans blue extravasation assay, coronal sections were cut into 2-mm slices and were photographed. The blue-stained area was defined as BBB permeable. For quantitative measurements, the ischemic hemispheres were homogenized in 3 mL of N, N-dimethylformamide (Sigma Aldrich), incubated for 18 hours at 55°C, and centrifuged [22]. The supernatants were analyzed at 620 nm by spectrophotometry.

12. Transmission electron microscopy (TEM)

Rats (n=3) were anesthetized and intracardially perfused with 0.1 M phosphate-buffered solution (PBS) containing 0.1% glutaraldehyde. The ischemia penumbras of rats were dissected and postfixed overnight at 4°C using 2.5% glutaraldehyde. Tissues were cut along the coronal plane at a thickness of 50 μm. Samples were processed for TEM observation as previously described [23].

13. Detection of proinflammatory cytokines

The tissue fluids of the ischemia penumbra were collected 24 h after reperfusion (n=5). Concentrations of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumour necrosis factor α (TNF-α) were examined using an ELISA kit following the manufacturer’s instructions (Biosource, Invitrogen, USA). Absorbance was measured at 450 nm using a microplate reader (Infinite M2000, TECAN, Switzerland).

14. Western Blot Analysis

Fifty mg of ischemic penumbra tissues (n=6) were used for Western blot analysis as previous described [15]. The primary antibodies include: mouse anti-VE-cadherin (1:1000, Cell Signaling Technology), rabbit anti-AQP4 (1:1000, Proteintech, USA), rabbit anti-Claudin-1 (1:1000, Abcam, USA), mouse anti-GFAP (1:1000, Cell Signaling Technology), rabbit anti-Iba1 antibody (1:500, Wako), goat anti-C3d antibody (1:1000, RD Systems), rabbit anti-TLR4 antibody (1:1000, Cell Signaling Technology), mouse anti-NF-κB antibody (1:1000, Abcam), mouse anti-GAPDH (1:1000, Cell Signaling Technology). The membranes were then incubated with the corresponding HRP-conjugated secondary antibody for 2 h. Protein bands were visualized using the LI-COR Odyssey System (LI-COR Biotechnology, USA).

15. Statistical Analysis

All data were analysed by an observer who was blind to the experimental protocol. Statistical calculations were performed with GraphPad Prism software, version 8.0. All results, except for neurological deficit scores, were expressed as mean ± standard deviation (SD), applying a two-way ANOVA with Tukey’s post hoc test to determine significant differences between the experimental groups. The neurological deficit scores were presented as median with interquartile range and were analyzed using two-tailed Mann-Whitney U tests. P values < 0.05 considered statistically significant.

1. CSO treatment significantly attenuated cerebral ischemic injury.

First, we used neurological scores and TTC staining to measure brain injury in the four groups. As shown in Figures 1A and 1B, the infarct volume in the MCAO-Con group was 32.5% ± 9.4% (^##p<0.01 vs. Sham-Con group). CSO treatment significantly decreased the infarct volume to 12.9% ± 3.9% (^*p<0.05 vs. MCAO-Con group). Additionally, as shown in Figure 1C, no significant difference was noted in the neurological scores of the rats between the Sham-Con and Sham-CSO groups. Compared with the Sham-Con group, the MCAO-Con group had significantly higher neurological scores, reflecting a worse neurological condition (^##p<0.01). Interestingly, the neurological scores of the rats in the MCAO-CSO group was dramatically reduced compared with that of the MCAO-Con group (^*p<0.05).

2. CSO treatment significantly alleviated neuronal injury in the ischemia penumbra.

HE, Nissl, Tunel, and Neun staining were performed to assess the neuronal damage and survival in the ischemic penumbra following MCAO-R injury (Figure 2). As shown in Figures 2A (a) and 2B, cells that were positive following HE staining (HE⁺) had a clear outline, compact structure, and intact nucleolus. The proportion of HE⁺ cells was 96.4% ± 3.5% in the Sham-Con group and 95.4% ± 2.8% in the Sham-CSO group, with no significant difference between the groups. The proportion of HE⁺ cells was 39.6% ± 1.2% in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO treatment significantly increased the proportion of HE⁺ cells to 75.1% ± 5.0% (^*p<0.05 vs. MCAO-Con group).

As shown in Figures 2A (b) and 2B, cells that were positive following Nissl staining (Nissl⁺) had intact neurons with flush cell bodies, while injured neurons had shrunken cell bodies accompanied by shrunken and pyknotic nuclei. The proportion of Nissl⁺cells was 95.9% ± 1.9% in the Sham-Con group and 95.5% ± 1.8% in the Sham-CSO group, with no significant difference between the groups. The proportion of Nissl⁺cells was 35.6% ± 5.2% in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO significantly increased the proportion of Nissl⁺cells to 63.6% ± 3.3% (^*p<0.05 vs. MCAO-Con group).

As shown in Figures 2A (c) and 2B, cells that were positive following Tunel staining (Tunel⁺) represented apoptotic nerve cells. The proportion of Tunel⁺ cells was 2.6% ± 0.5% in the Sham-Con group and 2.9% ± 0.6% in the Sham-CSO group, with no significant difference between the groups. The proportion of Tunel⁺ cells was 66.8% ± 3.1% in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO significantly decreased the proportion of Tunel⁺ cells to 31.2% ± 3.1% (^*p<0.05 vs. MCAO-Con group).

Finally, as shown in Figures 2A (d) and 2B, cells that were positive following Neun staining (Neun⁺) represented surviving neurons. The proportion of Neun⁺ cells was 96.7% ± 1.9% in the Sham-Con group and 95.0% ± 4.2% in the Sham-CSO group, with no significant difference between the groups. The proportion of Neun⁺ cells was 38.2% ± 3.1% in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO significantly increased the proportion of Neun⁺ cells to 65.5% ± 3.2% (^*p<0.05 vs. MCAO-Con group).

3. CSO treatment alleviated brain edema induced by ischemic stroke.

In order to determine the extent of brain edema 24 h after reperfusion, we measured brain water content and blood-brain barrier (BBB) permeability. As shown in Figure 3A, the brain water content was 75.0% ± 1.4% in the Sham-Con group and 76.0% ± 1.7% in the Sham-CSO group, with no significant difference between the groups. The brain water content was 83.1% ± 0.8% in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO significantly decreased the brain water content to 79.4% ± 0.6% (^*p<0.05 vs. MCAO-Con group).

As shown in Figures 3B and 3C, the content of Evans blue was 2.7 μg/ml ± 0.5 μg/ml in the Sham-Con group and 2.5 μg/ml ± 0.6 μg/ml in the Sham-CSO group, with no significant difference between the groups. The content of Evans blue was 19.8 μg/ml ± 1.1 μg/ml in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO significantly decreased the content of Evans blue to 13.9 μg/ml ± 2.8 μg/ml (^*p<0.05 vs. MCAO-Con group).

We next evaluated cerebral edema markers in the ischemia penumbra 24 h after reperfusion. In particular we focused on VE-cadherin, an important component of the BBB, and AQP4 and Claudin-1, which are strongly expressed by leaky brain microvessels. As shown in Figure 4A (a, b), western blot analysis indicated no significant differences in the expression of VE-cadherin, AQP4, or Claudin-1 between the Sham-Con and Sham-CSO groups. Twenty-four hours after reperfusion, the MCAO-Con group demonstrated significantly decreased expression of VE-cadherin and increased expression of AQP4 and Claudin-1 (^###p<0.001, ^##p<0.01, ^#p<0.05 vs. Sham-Con group). However, compared with the MCAO-Con group, the MCAO-CSO group had significantly higher expression of VE-cadherin and decreased expression of AQP4 and Claudin-1(^**p<0.01,^*p<0.05).

BBB disruption is the main pathological mechanism leading to ischemic brain edema, so we used transmission electron microscopy (TEM) to measure the BBB ultrastructure in the four groups of rats. As shown in Figure 4B, no obvious difference in the BBB ultrastructure was observed between the Sham-Con and Sham-CSO groups under physiological conditions. However, striking effects emerged in the MCAO groups, 24 h after reperfusion. Swollen astrocyte end-feet were clearly evident in the ischemic penumbra of the MCAO-Con and the MCAO-CSO groups, and the effect was exacerbated in the MCAO-Con group, which exhibited elevated astrocyte swelling, discontinuous plasma membranes, disturbed gap junctions, broken organelles, swollen endothelial cytoplasm and rough basal membranes. Finally, pretreatment with CSO significantly reduced the ultrastructure damage in MCAO-CSO group observed with TEM.

4. CSO treatment significantly inhibited TLR4/NF-κB mediated activation of microglia and astrocytes in the ischemia penumbra.

In the next set of analyses, we measured microglial and astrocytic activation in the ischemia penumbra across the four groups. As shown in Figure 5A (a, b), there were no obvious differences in microglial and astrocytic activation between the Sham-Con and Sham-CSO groups under physiological conditions. Compared with the Sham-Con group, the astrocytes (GFAP-positive) and microglia (Iba1-posittive) in the MCAO-Con group were more activated (^##p<0.01), as evident from large soma and short, coarse cytoplasmic and hypertophic processes. However, CSO significantly attenuated the microglial and astrocytic activation induced by MCAO-R injury (^*p<0.05 vs. MCAO-Con group). Additionally, we found that the activated microglia were close to the activated astrocytes in the ischemia penumbra in both the MCAO-Con and MCAO-CSO groups, indicating possible co-activation of microglia and astrocytes following ischemic stroke. In keeping with this conclusion, CSO significantly inhibited co-activation of microglia and astrocytes in the MCA-CSO group compared with the MCAO-Con group (Figure 5B).

In addition, we measured the protein expression of Iba1 and GFAP using western blot 24 h after reperfusion in the ischemia penumbra, representing the activation of microglia and astrocytes respectively. As shown in Figure 5C (a, b), there was no significant difference in expression of Iba1 or GFAP between the Sham-Con and Sham-CSO groups. The expression of Iba1 and GFAP in the MCAO-Con group was significantly higher than in the Sham-Con group (^##p<0.01). Remarkably, CSO treatment significantly decreased the expression of Iba1 and GFAP compared with the MCAO-Con group (^*p<0.05).

Finally, in order to further investigate whether microglia and astrocyte activation was mediated by TLR4 and NF-κB, we measured TLR4 and NF-κB expression levels in the ischemia penumbra. As shown in Figure 5C (a, b), no significant difference in TLR4 and NF-κB expression was found between the Sham-Con and Sham-CSO groups. TLR4 and NF-κB protein levels were significantly increased in the MCAO-Con group (^##p<0.01, ^#p<0.05 vs. Sham-Con group), and CSO significantly inhibited the expression of TLR4 and NF-κB compared with the MCAO-Con group (^*p<0.05).

5. CSO treatment significantly inhibited inflammation in the ischemia penumbra.

We measured the expression of proinflammatory cytokines (IL-1β, IL-6 and TNF-α) in the ischemia penumbra 24 h after reperfusion. As shown in Figure 6A (a), the level of IL-1β was 52.3 pg/mg protein ± 2.1 pg/mg protein in the Sham-Con group and 57.0 pg/mg protein ± 3.6 pg/mg protein in the Sham-CSO group, with no significant difference between the groups. The level of IL-1β was 107.3 pg/mg protein ± 11.0 pg/mg protein in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO significantly decreased the level of IL-1β to 69.3 pg/mg protein ± 4.0 pg/mg protein (^*p<0.05 vs. MCAO-Con group). As shown in Figure 6A (b), the level of IL-6 was 80.3 pg/mg protein ± 5.5 pg/mg protein in the Sham-Con group and 85.0 pg/mg protein ± 7.2 pg/mg protein in the Sham-CSO group, with no significant difference between the groups. The level of IL-6 was 275.7 pg/mg protein ± 15.3 pg/mg protein in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO significantly decreased the level of IL-6 to 123.3 pg/mg protein ± 10.1 pg/mg protein (^*p<0.05 vs. MCAO-Con group). As shown in Figure 6A (c), the level of TNF-α was 58.7 pg/mg protein ± 6.2 pg/mg protein in the Sham-Con group and 63.3 pg/mg protein ± 4.6 pg/mg protein in the Sham-CSO group, with no significant difference between the groups. The level of TNF-α was 121.9 pg/mg protein ± 7.7 pg/mg protein in the MCAO-Con group (^##p<0.01 vs. Sham-Con group), and CSO significantly decreased the level of TNF-α to 85.0 pg/mg protein ± 7.6 pg/mg protein (^*p<0.05 vs. MCAO-Con group).

In order to provide additional evidence of the effect of CSO on inflammation following ischemic stroke, we used immunofluorescence staining to detect the expression of the microglia marker IBA1 and pro-inflammatory factor TNF-α in the ischemia penumbra 24 h after reperfusion. As shown in Figure 6B, there was no significant difference in the expression level of IBA1 and TNF-α between the Sham-Con and Sham-CSO groups. The expression of IBA1 and TNF-α significantly increased in the MCAO-Con group compared with the Sham-Con group. Additionally, the levels of IBA1 and TNF-α in the MCAO-CSO group were markedly decreased compared to the MCAO-Con group. We also measured the expression of the astrocyte marker GFAP and pro-inflammatory factor TNF-α in the ischemia penumbra 24 h after reperfusion. As shown in Figure 6C, no significant difference in the expression of GFAP and TNF-α was noted between the Sham-Con and Sham-CSO groups. The expression of GFAP and TNF-α significantly increased in the MCAO-Con group compared to the Sham-Con group. Finally, rats in the MCAO-CSO group had significantly lower levels of GFAP and TNF-α than those in the MCAO-Con group.

6. CSO treatment inhibited A1 type reactive astrocytes and promoted A2 type reactive astrocytes in the ischemia penumbra.

We investigated the presence of A1 type astrocytes (labeled by C3d/GFAP) and A2 type astrocytes (labeled by S100A10/GFAP) in the ischemia penumbra across the four groups, and subsequently assessed the influence of CSO on the number of peri-infarct C3d/GFAP-positive cells and S100A10/GFAP-positive cells by performing immunofluorescence staining. As shown in Figure 7A (a, b, c), there was no significant difference in the number of C3d/GFAP-positive cells and S100A10/GFAP-positive cells between the Sham-Con and Sham-CSO groups. Additionally, C3d/GFAP-positive cells were significantly increased and S100A10/GFAP-positive cells were significantly decreased in MCAO-Con group compared with the Sham-Con group (^##p<0.01). The CSO-treated MCAO rats had significantly fewer C3d/GFAP-positive cells than did the rats in the MCAO-Con group (^*p<0.05), and the number of S100A10/GFAP-positive cells in the MCAO-CSO group was significantly greater than in the MCAO-Con group (^*p<0.05).

Next, we used western blot analysis to measure the protein expression of the A1 type astrocyte marker C3d in the ischemia penumbra. As shown in Figure 7B (a, b), there was no significant difference in C3d expression between the Sham-Con and Sham-CSO groups. The C3d protein level was markedly increased in the MCAO-Con group (^##p<0.01 vs. Sham-Con group) and this effect was reduced by CSO treatment (^*p<0.05).

Stroke accounts for almost 10% of all deaths worldwide, with the increasing global disability burden [1]. Over the past two decades, management of ischemic stroke has improved with the advent of intravenous thrombolytic treatment to restore blood flow to the brain, and more recently with the development of mechanical thrombectomy devices to remove blood clots responsible for strokes. However, these advances have not met with universal success because thrombolytic therapy is only effective within 4–6 hours after an ischemic attack [2, 3]. Accordingly, effective therapeutic strategies for the prevention and treatment of ischemic stroke are urgently required.

CSO is a common vegetable oil used in the manufacture of margarine and cooking in some countries [4]. Most of the scientific studies involving CSO use it as the solvent for lipid-soluble drugs such as estrogen and ketorolac [5, 6]. An influential animal study published in Science found that in dogs, thrombosis and thromboembolic disease associated with atherosclerosis occurred with diets containing beef tallow and lard or coconut oil but not with diets using CSO as a source of fat. These results supported the conclusion that CSO may provide the basis for therapeutic intervention strategies against thromboembolic diseases [9]. However, the effect of CSO on ischemic stroke has not been explored before. In this study, we found that CSO treatment significantly improved neurological deficits, reduced infarction volume, and increased neuronal survival in the ischemic penumbra, suggesting that CSO could be a new strategy for preventing ischemic stroke. It is worth noting that CSO as a drug solvent is commonly administered by subcutaneous injection [5, 6], so we employed subcutaneous injection in the current study. Additionally, CSO is edible but it is not clear whether edible CSO is neuroprotective, which is a question that should be addressed in future research. Additionally, while the current results are promising, the detailed molecular mechanisms by which CSO may be neuroprotective remain unclear.

Several studies have shown that CSO possesses a wide array of health benefits against peripheral tissue injury via its anti-inflammatory effects [7, 8]. For example, one recent study found that CSO treatment protected against inflammatory bowel disease (IBD) by reducing the expression of inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-17 [7]. Another study reported that ketorolac in saline produced 8 h of effective antinociception and anti-inflammation, whereas ketorolac in CSO vehicles produced 78 h of antinociception and anti-inflammation [5]. While these results are promising, previous research has not specifically examined the effects of CSO on the neuroinflammation induced by ischemic stroke injury.

Neuroinflammation induced by activated microglia and astrocytes contributes substantially to ischemic stroke injury [10, 11, 12]. Immediately after ischemic stroke, microglia and astrocytes are excessively activated, as evident from large cell bodies and hypertrophic processes, and they release robust levels of inflammatory cytokines, such as IL-1, IL-6, and TNF-α, which contribute to severe inflammatory responses and aggravate brain injury [10, 11, 12]. Inhibiting the activation of microglia and astrocytes during ischemic stroke could significantly alleviate this brain injury [24]. In the current study, we evaluated the effect of CSO on neuroinflammatory processes after ischemic stroke injury which are mediated by microglia and astrocyte activation. We found CSO treatment significantly inhibited the hyperactivation of microglia and astrocytes and significantly decreased the expression levels of proinflammatory cytokines (IL-1β, IL-6 and TNF-α) in the ischemia penumbra after MCAO-R injury. However, the underlying mechanism remains unclear.

Toll-like receptor 4 (TLR4) is primarily expressed in microglia and mediates microglial activation and inflammatory response [25], and we have previously found that inhibition of TLR4 can attenuate ischemic stroke injury [15]. In addition, the transcription factor NF-κB plays a pivotal role in initiating neuroinflammation following ischemic stroke; activating NF-κB significantly promotes the expression and secretion of the inflammation-related genes both in microglia and astrocytes [26]. Our previous research indicates that decreasing the expression of NF-κB significantly alleviates cerebral ischemia injury [27], and another recent study verified that suppression of the TLR4/NF-κB signaling pathway improved cerebral ischemia-reperfusion injury in rats [28]. In the current study, we found that CSO significantly inhibited TLR4 and NF-κB expression in the ischemia penumbra after MCAO-R injury. Thus, we conclude that CSO treatment significantly inhibits TLR4/NF-κB mediated activation of microglia and astrocytes and the downstream inflammatory response, providing a potential mechanism for the neuroprotective mechanism of CSO against ischemic stroke. However, further research is needed to identify the receptors and signaling pathways involved in CSO’s regulation of TLR4 and NF-κB.

Previous research has reported evidence of crosstalk between astrocytes and microglia, which may contribute to the neuroinflammation that ultimately induces postoperative cognitive dysfunction (POCD) [29]. In LPS treated co-cultures of astrocytes and microglia, microglia P2Y₆ receptors induce the release of nitric oxide, which causes astrocyte apoptosis [30]. In the current study, we found that some of the activated microglia and astrocytes were adjacent to each other in the penumbra, indicating potential “co-activation” and interaction between activated microglia and astrocytes. We also found that CSO treatment markedly reduced this co-activation. Recent studies indicate that ischemic stroke induces two types of astrocyte activation. One is the neurotoxic A1 type, which is induced by activated microglia that secrete IL-1α, TNFα and C1q; A1 type astrocytes can release neurotoxic complement C3d, leading to neuronal death. The second type is the neuroprotective A2 type, which promotes neuronal survival and tissue repair [17, 18]. We found that CSO treatment significantly decreased A1 type astrocyte activation (as evident from the downregulation of C3d expression) and increased A2 type astrocyte activation. Additionally, we identified NF-κB as the key molecule that mediates A1 type astrocyte activation [17]. Taken together, these findings indicate that CSO treatment inhibited TLR4-mediated microglial activation and TNF-α secretion, thereby inhibiting NF-κB-mediated A1 astrocyte activation and reducing C3d expression and secretion, ultimately alleviating neuronal damage induced by ischemic stroke injury (Fig. 8).

Brain edema is a life-threatening consequence of stroke, potentially leading to brain herniation and death [31]. We found that CSO treatment alleviated brain edema by protecting the blood–brain barrier (BBB) integrity, increasing BBB associated protein expression and reducing vascular destruction. Activated microglia and astrocytes increase neuroinflammation which leads to the disruption of BBB [12], and our results indicate that CSO alleviates BBB damage and brain edema induced by ischemic stroke by inhibiting inflammation. These promising results suggest the need for further research into the specific mechanisms underpinning CSO’s BBB-protective effects.

In conclusion, the current findings indicate that CSO treatment can alleviate ischemic stroke injury via mechanisms involving inhibiting TLR4/NF-κB pathway mediated inflammatory microglia and A1 type neurotoxic astrocyte activation. Our results suggest that CSO treatment is an attractive strategy for prevention of ischemic stroke.

BBB: blood–brain barrier; CNS: central nerve system; CSO: Cottonseed oil; GFAP: glial fibrillary acidic protein; HE: Hematoxylin and eosin; IBD: inflammatory bowel disease; IL-1β: interleukin-1β; IL-6: interleukin-6; MCAO-R: Middle cerebral artery occlusion and reperfusion; PBS: phosphate-buffered solution; POCD: postoperative cognitive dysfunction; SD: standard deviation; TLR4: Toll-like receptor 4; NF-κB: nuclear factor kappa B; TEM: Transmission electron microscopy; TTC: 2,3,5-triphenyltetrazolium chloride; TNF-α: tumour necrosis factor α

Acknowledgments

Not applicable

Authors’ contributions

M Liu, ZP Xu, and L Wang conducted most of the experiments and drafted the manuscript. LX Zhang, Y Liu, H Li and JS Lou contributed to the statistical analysis and manuscript editing. JB Cao, Q Fu, YH Liu and WG Hou contributed to data interruption. YL Ma and WD Mi designed this study and edited the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (no. 81801193, 81801138, 81471119, 81671039, 81971226).

Consent for publication

Not applicable.

Ethics approval and consent to participate
The experimentation procedures were approved by the Animal Care Committee of the First Medical Center of Chinese PLA General Hospital (Beijing, China). The maintenance and handling of the rats were consistent with the guidelines of the National Institutes of Health, and adequate measures were taken to minimize animal discomfort.

Availability of data and materials

The datasets during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing Interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Feigin Valery L, Krishnamurthi Rita V, Parmar P. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990–2013: The GBD 2013 Study. Neuroepidemiology. 2015;45:161–76.
Lo EH, Broderick JP, Moskowitz MA. tPA and proteolysis in the neurovascular unit. Stroke. 2004;35:354–6.
The Lancet. 21st century management and prevention of stroke. Lancet. 2018;392:1167.
Jones LA, King CC. Cottonseed oil. In: Hui YH, editor, Bailey’s Industrial Oil and Fat Products, 5th edn. Vol 2. Edible Oils and Fat Products: Oils and Oil Seeds. New York: John Wiley. 1996;pp:159–240.
Wang LK, Wang PJ, Hou CH, Chu CC, Tzeng Jann-Inn, Shieh Ja-Ping, et al. The antinociceptive and anti-inflammatory effects of five depot formulations of ketorolac propyl ester in rats. Acta Anaesthesiol Taiwan. 2005;43:85–92.
Aizawa Naoki I, Kazuyoshi R, Jan S, Downs Thomas R, Igawa Yasuhiko A, Karl-Erik, et al. Comparison of the effects of oestrogen deficiency and old age on primary bladder afferent activity and voiding behaviour in the ageing female rat. BJU Int. 2011;108:E10-6.
Park J-S, JeongWon C, Jae-Kyung HSun-Hee,K, Seon-Young KEun-Kyung,L, et al. Cottonseed Oil Protects Against Intestinal Inflammation in Dextran Sodium Sulfate-Induced Inflammatory Bowel Disease. J Med Food. 2019;22:672–9.
Wilhelmi G. Potential effects of nutrition including additives on healthy and arthrotic joints. I. Basic dietary constituents. Z Rheumatol. 1993;52:174–9.
Mahley R, Nelson AW, Ferrans VJ, Fry DL. Thrombosis in association with atherosclerosis induced by dietary perturbations in dogs. Science. 1976;192:1139–41.
Lo EH, Moskowitz MA, Jacobs TP. Exciting, radical, suicidal: how brain cells die after stroke. Stroke. 2005;36:189–92.
Chamorro Ángel D, Ulrich U, Xabier, Planas Anna M. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 2016;15:869–81.
Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, Shi FD. Global brain inflammation in stroke. Lancet Neurol. 2019;18:1058–66.
Zhao SC, Ma LS, Chu ZH, Xu H, Wu WQ, Liu F. Regulation of microglial activation in stroke. Acta Pharmacol Sin. 2017;38:445–58.
Zhang B, Zhang HX, Shi ST, Bai YL, Zhe X, Zhang SJ, et al. Interleukin-11 treatment protected against cerebral ischemia/reperfusion injury. Biomed Pharmacother. 2019;115:108816.
Zhang ZL, Qin P, Deng YL, Ma Z, Guo H, Guo HY, et al. The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation. J Neuroinflammation. 2018;15:206.
Guo H, Yang J, Liu M, Wang L, Hou W, Zhang L, et al. Selective activation of estrogen receptor β alleviates cerebral ischemia neuroinflammatory injury. Brain Res. 2020;1726:146536.
Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46:957–67.
Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481–7.
Liu SB, Zhang N, Guo YY, Zhao R, Shi TY, Feng SF, et al. G-protein-coupled receptor 30 mediates rapid neuroprotective effects of estrogen via depression of NR2B-containing NMDA receptors. J Neurosci. 2012;32:4887–900.
Wang Q, Li X, Chen Y, Wang F, Yang Q, Chen S, et al. Activation of epsilon protein kinase C-mediated anti-apoptosis is involved in rapid tolerance induced by electroacupuncture pretreatment through cannabinoid receptor type 1. Stroke. 2011;42:389–96.
Hatashita S, Hoff JT, Salamat SM. Ischemic brain edema and the osmotic gradient between blood and brain. J Cereb Blood Flow Metab. 1988;8:552–9.
Kim GW, Gasche Y, Grzeschik S, Copin J-C, Maier CM, Chan PH. Neurodegeneration in striatum induced by the mitochondrial toxin 3-nitropropionic acid: role of matrix metalloproteinase-9 in early blood-brain barrier disruption? J Neurosci. 2003;23:8733–42.
Relucio J, Menezes MJ, Miyagoe-Suzuki Y, Takeda S, Colognato H. Laminin regulates postnatal oligodendrocyte production by promoting oligodendrocyte progenitor survival in the subventricular zone. Glia. 2012;60:1451–67.
Wang Qing TX, Nan, Yenari Midori A. The inflammatory response in stroke. J Neuroimmunol. 2007;184:53–68.
Rahimifard M, Maqbool F, Moeini-Nodeh S, Niaz K, Abdollahi M, Braidy N, et al. Targeting the TLR4 signaling pathway by polyphenols: a novel therapeutic strategy for neuroinflammation. Ageing Res Rev. 2017;36:11–9.
Ridder DA, Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience. 2009;158:995–1006.
Deng YL, Ma YL, Zhang ZL, Zhang LX, Guo H, Qin P, et al. Astrocytic N-Myc Downstream-regulated Gene-2 Is Involved in Nuclear Transcription Factor κB-mediated Inflammation Induced by Global Cerebral Ischemia. Anesthesiology. 2018;128:574–86.
Zhao H, Chen Z, Xie LJ, Liu GF. Suppression of TLR4/NF-κB Signaling Pathway Improves Cerebral Ischemia-Reperfusion Injury in Rats. Mol Neurobiol. 2018;55:4311–9.
Xu J, Dong H, Qian Q, Zhang X, Wang Y, Jin W, et al. Astrocyte-derived CCL2 participates in surgery-induced cognitive dysfunction and neuroinflammation via evoking microglia activation. Behav Brain Res. 2017;332:145–53.
Quintas C, Pinho D, Pereira C, Saraiva L, Gonçalves J, Queiroz G. Microglia P2Y₆ receptors mediate nitric oxide release and astrocyte apoptosis. J Neuroinflammation. 2014;11:141.
Wijdicks EF, Sheth KN, Carter BS, Greer DM, Kasner SE, Kimberly WT, et al. Recommendations for the management of cerebral and cerebellar infarction with swelling: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:1222–38.

SupplementaryMaterial.docx

Download PDF

Journal Publication

published 11 Sep, 2020

Read the published version in Journal of Neuroinflammation →

Editorial decision: Major Revision
14 Jul, 2020
Review #2 received at journal
10 Jul, 2020
Reviewer #2 agreed at journal
04 May, 2020
Review #1 received at journal
16 Apr, 2020
Reviewer #1 agreed at journal
13 Apr, 2020
Reviewers invited by journal
12 Apr, 2020
Editor invited by journal
09 Apr, 2020
Editor assigned by journal
08 Apr, 2020
First submitted to journal
07 Apr, 2020
Submission checks completed at journal
07 Apr, 2020

You are reading this latest preprint version

Cottonseed oil alleviates ischemic stroke injury by inhibiting the inflammatory activation of microglia and astrocyte

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Methods and Materials

Results

Discussion

Conclusion

Abbreviations

Declarations

References

Supplementary Files

Status:

Journal Publication

Version 1